Immunomodulatory Alpha Neutrophils
Having long been recognised as crucial mediators of innate immunity, neutrophils provide the first line of defence against invading microorganisms and inflammatory insults, capable of mobilizing innate and adaptive responses to return to homeostasis.
At LIfT Biosciences, we are producing a unique type of innate immune cell called Immunomodulatory Alpha Neutrophils (IMAN). IMANs exhibit a dual mode of action that enables them to be exceptionally cytotoxic both directly and also by recruiting the rest of the immune system to destroy solid tumours. LIfT is the only biotechnology company in the world with a neutrophil based cell therapy platform.
N-LIfT cells differentiate in vivo into IMANs that have the potential to overcome hurdles encountered by other cell therapies in the treatment of solid tumours. IMANs are:
Allogeneic, straightforward to scale, cost effective and off-the-shelf
Innate antigen-independent mechanism-of-action
Actively recruited into the tumour microenvironment
Stable and capable of overcoming immunosuppressive tumour microenvironments
Capable of orchestrating patients own anti-tumour immune responses